# Verdict: unicameral_bone_cyst.md

1. DOSE LEAK: none. Grepped the sidecar for any digit — the only match is "12th" in the
   citation line ("... Oncology, 12th ed. text was searched ..."), which is the edition
   number, not a dose/mg/mg-m2/AUC/schedule number. No numeric dose, injectate volume, or
   procedural quantity anywhere in the file.

2. UNGROUNDED CLAIMS: none beyond what the sidecar already discloses. Verified independently:
   - Grepped DeVita for "unicameral bone cyst", "simple bone cyst", "solitary bone cyst",
     "SBC", "UBC" — no dedicated section. (Note: "SBC" hits in DeVita are all "small bowel
     cancer", an unrelated false-positive acronym collision — correctly not used by the draft.)
   - Grepped DeVita for "bone cyst" generally — only two hits, both aneurysmal-bone-cyst /
     myositis-ossificans genetics (USP6 translocation), unrelated to UBC management — matches
     the draft's own disclosure exactly.
   - Grepped DeVita for the specific modalities the sidecar names (corticosteroid,
     bone marrow aspirate, curettage, bone graft, decompression, aneurysmal bone cyst) — all
     hits are unrelated contexts (GVHD prophylaxis, biliary/optic-nerve decompression,
     mandibular ameloblastoma recurrence, etc.), none supporting UBC-specific management.
   - Every clinical sentence in the body is explicitly tagged "(general oncology standard,
     not from DeVita's section on this disease)" — this is honest and consistent with the
     grep results, not a fabrication dressed as sourced. The content itself (observation for
     latent/asymptomatic cysts; intralesional steroid/BMA injection or decompression first-
     line; curettage + bone grafting for refractory/high-risk; fracture allowed to unite
     before definitive cyst treatment; serial radiograph monitoring; MRI/CT reserved for
     atypical lesions; referral criteria for aggressive-appearing lesions or recurrent
     fracture) is uncontroversial, textbook orthopaedic-oncology standard of care for this
     benign entity — no specific trial, statistic, or brand-name regimen is asserted anywhere,
     so there is nothing here needing DeVita grounding that isn't already flagged.
   - No trial names, no statistics (recurrence %, healing rate, etc.), no specific drug/agent
     name (e.g., no named corticosteroid, no named bone-substitute product) are given — the
     draft's "Deliberately omitted" section confirms this was intentional, not an oversight.

3. CITATION: present. Line 76-79: "DeVita, Hellman, and Rosenberg's Cancer: Principles &
   Practice of Oncology, 12th ed." — name only, no page numbers. Correctly also states NCCN
   is inapplicable (benign entity) and explicitly states no claim in the document is
   DeVita-sourced, which is accurate per the grep results above.

4. VERDICT: CLEAN (ready for R1).
   This sidecar is a rare, correct instance of the "no DeVita section exists" case: it
   discloses the negative search result up front, tags every single clinical claim as
   general-standard rather than falsely attributing it to DeVita, contains zero numeric
   dose/schedule leakage, and omits drug names/statistics/technique specifics that couldn't be
   grounded. No fabrication found on independent re-grep.
